RECURSION PHARMACEUTICALS, INC. RXRX

Rank #2190 · Nasdaq · $0.7B market cap

Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.

Score

29.9

P/E

-2.1

P/B

1.40

ROE

-67.5%

Op. Margin

-785.3%

Debt Ratio

85%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.1x, P/B 1.40x. Ranks in the top 58% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -67.5%. Ranks in the top 93% of the universe.

Safety ★★★☆☆

Good

Debt ratio 85%. Ranks in the top 34% of the universe.

Growth ★★★★☆

Good

Revenue growth of 11.9% year over year. Ranks in the top 30% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	$0.0B	$-0.1B	$-0.1B	$-0.1B	-2692.6	-89
2022	$0.0B	$-0.1B	$-0.1B	$-0.1B	-2135.7	-54
2023	$0.0B	$-0.2B	$-0.2B	$-0.2B	-1795.8	-104
2024	$0.0B	$-0.2B	$-0.2B	$0.5B	-616.7	35
2025	$0.0B	$-0.4B	$-0.3B	$0.5B	-785.3	85